|
Case
|
Age
|
Sex
|
sCre
|
M-Alb/cre (mg/g cre)
|
HT
|
Duration of disease prior to biopsy (months)
|
Hematuria
|
Previous Treatment
|
|---|
|
FGS 1
|
45
|
M
|
0.61
|
6087
|
+
|
1
|
2+
|
ARB
|
|
Statin
|
|
FGS 2
|
47
|
M
|
3.50
|
4338
|
+
|
12
|
1+
|
ARB
|
|
CCB
|
|
statin
|
|
MC 1
|
24
|
M
|
0.71
|
3376
|
-
|
1
|
2+
|
-
|
|
MC 2
|
27
|
M
|
0.65
|
2868
|
-
|
1
|
1+
|
-
|
|
Amy1
|
73
|
M
|
0.83
|
4680
|
-
|
4
|
1+
|
-
|
|
Amy 2
|
82
|
F
|
0.65
|
5381
|
+
|
1
|
2+
|
ARB
|
|
Statin
|
|
Amy 3
|
72
|
F
|
0.9
|
3600
|
-
|
48
|
2+
|
ARB
|
|
ConB1
|
44
|
M
|
-
|
-
|
-
|
-
|
-
|
-
|
|
ConB2
|
66
|
M
|
-
|
-
|
-
|
-
|
-
|
-
|
|
ConB3
|
78
|
M
|
-
|
-
|
-
|
-
|
-
|
-
|
- sCre serum creatinine (mg/dL), ARB angiotensin II type 1 receptor blocker, CCB calcium channel blocker, MC minimal change, FGS focal segmental glomerular sclerosis, Amy AL amyloidosis, ConB1-3 three age-matched control, which were not obtained in a series of consecutive patients
